EUVIMEDEUVIMED entdecken
Crossref

Redaporfin Development for Photodynamic Therapy and its Combination with Glycolysis Inhibitors †

Maria Inês P Mendes iD, Luis G Arnaut iD

Photochemistry and Photobiology · 2023

DOI: 10.1111/php.13770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Photochemistry and Photobiology, 2023. Verfasst von Maria Inês P Mendes und 1 weiteren Autor:innen. Beteiligte Einrichtung: CQC-IMS, Department of Chemistry, University of Coimbra, Coimbra, Portugal. Hauptthemen laut MEDLINE: Photochemotherapy, Porphyrins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Photodynamic therapy (PDT) remains an underutilized treatment modality in oncology. Many efforts have been dedicated to the development of better photosensitizers, better formulations and delivery methods, rigorous planning of light dose distribution in tissues, mechanistic insight, improvement of treatment protocols and combinations with other therapeutic agents. Hopefully, progress in all these fields will eventually expand the use of PDT. Here we offer a brief review of our own contribution to the development of a photosensitizer for PDT – redaporfin – currently in Phase II clinical trials, and present data on its combination with two glycolysis inhibitors: 2‐deoxyglucose and 3‐bromopyruvate. We show that 3‐bromopyruvate is more cytotoxic to a carcinoma cell line (CT26) than to a normal fibroblast (3T3) cell line, and that this selectivity is maintained in the in vitro combination with redaporfin‐PDT. This combination was investigated in BALB/c mice with large subcutaneous CT26 tumors and it is shown that the cure rate in the combination is higher (33% cures) than in PDT (11% cures) or in 3‐bromopyruvate (no cures) alone. The combination of redaporfin‐PDT with 3‐bromopyruvate illustrates the potential of combination therapies and how PDT benefits can be enhanced by systemic drugs with complementary targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyPorphyrinsMiceAnimalsPhotosensitizing AgentsSulfonamidesPyruvates

Substanzen

PorphyrinsPhotosensitizing AgentsredaporfinSulfonamidesbromopyruvatePyruvates

Autor:innen und Institutionen

  • CQC-IMS, Department of Chemistry, University of Coimbra, Coimbra, Portugal.

ORCID-Profile: Maria Inês P Mendes, Luis G Arnaut

Förderung

  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Mendes, M. I. P., & Arnaut, L. G. (2023). Redaporfin Development for Photodynamic Therapy and its Combination with Glycolysis Inhibitors †. Photochemistry and Photobiology. https://doi.org/10.1111/php.13770

Vancouver

Mendes MIP, Arnaut LG. Redaporfin Development for Photodynamic Therapy and its Combination with Glycolysis Inhibitors †. Photochemistry and Photobiology. 2023. doi:10.1111/php.13770

BibTeX
@article{Mendes2023,
  author = {Mendes, Maria Inês P and Arnaut, Luis G},
  title = {Redaporfin Development for Photodynamic Therapy and its Combination with Glycolysis Inhibitors †},
  journal = {Photochemistry and Photobiology},
  year = {2023},
  doi = {10.1111/php.13770}
}
Kostenlos starten →